First Use of Speedboat® UltraSlim in Latin America

Our latest device, Speedboat® UltraSlim, has now been successfully used in Latin America for the first time.

Speedboat® UltraSlim was used at the Ecuadorian Institute of Digestive Diseases (“IECED”) in late December, where Dr Carlos Robles Medranda, Dr Michel Kahaleh and Dr Eduardo Albéniz, supported by the Creo clinical team, performed 12 procedures using Speedboat® UltraSlim over three days, as well as performing the first ever F-POEM procedure with the device. F-POEM (Endoscopic Fundoplication Peroral Endoscopic Myotomy) is a minimally invasive endoscopic procedure used to treat oesophageal motility disorders in patients who are prone to gastroesophageal reflux.

 

Following the limited market release of Speedboat® UltraSlim in December 2023 the device has been successfully used in multiple clinical applications and was used in the UK, USA to treat precancerous lesions in the colon, oesophagus and stomach, in addition to performing oesophageal and gastric POEM procedures (a procedure which addresses swallowing disorders and gastroparesis).

Carlos Robles-Medranda, Head of the Endoscopy Service at IECED, said:

"I had the privilege of hosting these distinguished physicians, facilitating the successful execution of 12 procedures over three days using Speedboat UltraSlim. The excitement around the device was noticeable, and we eagerly anticipate the positive impact it will have on enhancing our patient pathways as we look to address an increased number of cases."

Dr Michel Kahaleh, who performed many of these procedures at IECED, commented:

"From the very first time when I saw the device, I knew that it was born to do POEM procedures. It allowed me to glide over the muscularis when tunnelling. Once you have acquired the knowledge to use this technology, you’re really going to save procedure time. The technology allows the endoscopist to complete an F-POEM procedure with a single device, whereas previously it required three different devices."

Craig Gulliford, Chief Executive Officer of Creo Medical, said:

"The procedures performed at IECED have shown the full potential of the new Speedboat UltraSlim. We were thrilled to witness the successful execution of the F-POEM procedure using solely the Speedboat device, a task that traditionally requires three separate instruments. This not only showcases the device's efficiency but also enhances the cost-effectiveness of the procedure, underscoring the economic advantages Creo’s technology can deliver to our valued customers."

Posted 10/01/2024

For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)

Read

13 May 2024

Directorate Changes - May 2024

Read

07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation

Read

02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital

Read

24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings

Read

19 March 2024

Welsh Labour Leader visits Creo’s facilities

Read

05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi

Read

31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific

Read

13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch

Read

01 November 2023

Speedboat® UltraSlim: US FDA Clearance

Read